Kura Oncology, Inc. (KURA) Covered Calls

You can sell covered calls on Kura Oncology, Inc. to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for KURA (prices last updated Mon 12:30 PM ET):

Kura Oncology, Inc. (KURA) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
10.36 +0.66 10.36 10.37 2.2M - 0.8
Covered Calls For Kura Oncology, Inc. (KURA)
Expiration Strike Call Bid Net Debit Return
If Flat		 Annualized
Return If Flat
Nov 21 10 1.05 9.32 7.3% 103%
Dec 19 10 2.30 8.07 23.9% 162%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial

Extended Business Description

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancers. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia. It is also developing KO-947, a small molecule inhibitor of extracellular signal related kinase used for the treatment of patients with tumors that have mutations in, or other dysregulation of, the mitogen-activated protein kinase; and KO-539, a small molecule inhibitor of the menin-mixed lineage leukemia. The company was founded in 2014 and is headquartered in San Diego, California.